Unity Biotechnology - UBX Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued twelve-month target prices for Unity Biotechnology's stock. Their UBX share price forecasts range from $10.00 to $80.00. On average, they anticipate the company's stock price to reach $35.60 in the next year. This suggests a possible upside of 1,149.1% from the stock's current price.
View analysts price targets for UBX or view top-rated stocks among Wall Street analysts.

Unity Biotechnology's stock was trading at $14.60 on January 1st, 2022. Since then, UBX shares have decreased by 80.5% and is now trading at $2.85.
View the best growth stocks for 2022 here.

Unity Biotechnology saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 820,100 shares, an increase of 333.2% from the October 31st total of 189,300 shares. Based on an average daily volume of 691,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 6.5% of the company's stock are short sold.
View Unity Biotechnology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our UBX earnings forecast.

Unity Biotechnology, Inc. (NASDAQ:UBX) announced its quarterly earnings data on Tuesday, November, 8th. The company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($0.99) by $0.37.

Unity Biotechnology shares reverse split before market open on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Unity Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include ARCH Venture Management LLC (75.06%), Vanguard Group Inc. (31.27%), Empery Asset Management LP (31.09%), Altium Capital Management LP (30.09%), 683 Capital Management LLC (19.89%) and Renaissance Technologies LLC (11.15%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends.

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UBX stock can currently be purchased for approximately $2.85.

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $40.45 million and generates $4.78 million in revenue each year. The company earns $-60,720,000.00 in net income (profit) each year or ($7.86) on an earnings per share basis.

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.